New Collaboration Between Novartis and Africa Medical Supplies Platform to Facilitate Supply of COVID-19 Related Medicines

Sep 1, 2020 1:15 AM ET
Summary: 
  • The collaboration aims to help alleviate supply and logistical constraints in the African Union member states
     
  • Portfolio of 15 generic and over-the-counter (OTC) medicines from Sandoz division will be sold at zero-profit to governments through Africa Medical Supplies Platform (AMSP) to 55 African and 15 Caricom eligible countries
     
  • The African Union through the AMSP has integrated vetted medical suppliers to ensure rapid access to affordable COVID-19 related supplies
Press Release

BASEL, Switzerland, September 1, 2020 /3BL Media/ — Novartis and the African Union (AU) through the Africa Medical Supplies Platform (AMSP) have announced a new collaboration to facilitate the supply of medicines from the Novartis Pandemic Response Portfolio to the AU member states and Caricom countries.

The AMSP portal is an online marketplace that enables the supply of COVID-19-related critical medical equipment in Africa. It was developed under the leadership of the AU Special Envoy, Strive Masiyiwa and powered by Janngo, on behalf of Africa Centres for Disease Control and Prevention (Africa CDC). The platform was also developed in partnership with African Export-Import Bank (Afreximbank) and the United Nations Economic Commission for Africa (ECA).

This collaboration aims to help alleviate supply and logistical constraints by ensuring efficient and rapid access to the Pandemic Portfolio medicines to African and Caricom governments. The AU comprises 55 Member States, representing all the countries on the African continent, while 15 Caricom countries are eligible for the Pandemic Portfolio.

“Our collaboration with AMSP is a continuation of our efforts at Novartis to combat COVID-19 across the world,” said Vas Narasimhan, CEO of Novartis. “Together, we are aiming to accelerate and expand access to affordable essential medicines in Africa to meet the very urgent patient needs across the continent as it continues battling this pandemic.”

AMSP was developed to ease the difficulties and open up the medical supplies market to Africa, and as part of the Partnership to Accelerate COVID-19 Testing (PACT) of Africa CDC. It integrates African and globally vetted medical suppliers to ensure cost-effectiveness and transparency in the procurement and distribution of COVID-19 related supplies.

"Following the successful listing of test kits, personal protective equipment, and clinical management devices, the African Union Chairperson has expanded our mandate to include groundbreaking medicines to treat COVID-19 patients in Africa,” said African Union Special Envoy, Strive Masiyiwa. “As a global pharmaceutical leader, Novartis is a strategic partner for AMSP to unlock access to the latest and best-performing medicines for Africans in an affordable way.”

Following the onset of the COVID-19 pandemic and its spread worldwide, there was a shortage of diagnostics, medical supplies and essential medical equipment such as personal protective equipment for healthcare workers, face masks, ventilators, and many others. Many African governments had severe challenges with the procurement of essential supplies to support their response activities and face stiff competition with the more industrialized countries for the limited available supplies.

As a continental body, we are working with several partners to ensure smooth and predictable access to essential medical supplies,” said Dr John Nkengasong, Director of Africa CDC. “We found that during the Ebola outbreak in 2014, many people died because of Ebola but not due to Ebola. This is because they did not have access to essential medicines needed for treatment.  With AMSP, countries don’t have to search the market for supplies. The prices are negotiated and fixed to unlock the supply space.”

The Novartis Pandemic Response Portfolio from Sandoz, the generics and biosimilar division of Novartis, comprises 15 medicines: Amoxicillin, Ceftriaxone, Clarithromycin, Colchicine, Dexamethasone, Dobutamine, Fluconazole, Heparin, Levofloxacin, Loperamide, Pantoprazole, Prednisone, Prednisolone, Salbutamol, Vancomycin. The portfolio was launched in July 2020 and sells medicines at zero-profit to governments, Non-Governmental Organizations (NGOs) and other institutional customers in up to 79 eligible countries to address the urgent unmet needs of low-and lower-middle-income countries for medicines to be used for symptomatic treatment at various stages of COVID-19. Eligible countries must be included on the World Bank’s list of LICs & LMICs1.

Disclaimer

This media update contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “seek,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” “aims,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this media update, or regarding potential future revenues from such products; or regarding collaboration efforts between Novartis and Africa Medical Supplies Platform to facilitate the supply of medicines from the Novartis Pandemic Response Portfolio to African Union member states and Caricom countries . You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this media update will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future, or that the activities and efforts related to ensuring efficient and rapid access to the Novartis Pandemic Response Portfolio medicines to African and Caricom governments described in this media update will be achieved or succeed in the expected time frame or at all. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases such as COVID-19; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this media update as of this date and does not undertake any obligation to update any forward-looking statements contained in this media update as a result of new information, future events or otherwise.

About Novartis

Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 109,000 people of more than 140 nationalities work at Novartis around the world. Find out more at

https://www.novartis.com.

 

Novartis is on Twitter. Sign up to follow @Novartis at https://twitter.com/novartisnews

For Novartis multimedia content, please visit https://www.novartis.com/news/media-library

For questions about the site or required registration, please contact media.relations@novartis.com

 

About AMSP

The Africa Medical Supplies Platform (AMSP) is a non-profit initiative launched by the African Union as an immediate, integrated and practical response to the Covid-19 pandemic. The online platform was developed under the leadership of the African Union Special Envoy, Strive Masiyiwa and powered by Janngo on behalf of the African Union’s Africa Centres for Disease Control and Prevention (Africa CDC) and in partnership with African Export-Import Bank (Afreximbank) and United Nations Economic Commission for Africa (ECA) with the support of leading African & international Institutions, Foundations & Corporations as well as Governments of China, Canada & France.

For more information visit https://www.amsp.africa 

About Janngo

Janngo builds, grows and invests in pan-African digital champions with proven business models and inclusive social impact. It builds digital ecosystems in high growth sectors by providing business support and digital platforms allowing Small and Medium Enterprises (SMEs) to scale and contribute to the economic empowerment of youth and women through job creation and capacity building.

For more information visit www.janngo.africa

About Africa CDC

Africa CDC is a specialized technical institution of the African Union that strengthens the capacity and capability of Africa’s public health institutions as well as partnerships to detect and respond quickly and effectively to disease threats and outbreaks, based on data-driven interventions and programmes.

Learn more at: http://www.africacdc.org

References

1.      https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups

# # #

 

Novartis Media Relations

E-mail: media.relations@novartis.com

 

Antonio Ligi

Novartis External Communications

+41 61 324 1374

antonio.ligi@novartis.com

 

Eric Althoff

Novartis US External Communications

+1 646 438 4335

eric.althoff@novartis.com

 

Katrina Lucking

Novartis Global Health & CR Communications

+41 79 484 7625

katrina.lucking@novartis.com

 

Beatrice Gachenge

Head of Communications, sub-Saharan Africa

beatrice.gachenge@novartis.com

+254721546660

 

 

Novartis Investor Relations

Central investor relations line: +41 61 324 7944

E-mail: investor.relations@novartis.com

 

Central

 

North America

 

Samir Shah

+41 61 324 7944

Sloan Simpson

+1 862 778 5052

Thomas Hungerbuehler

Isabella Zinck

+41 61 324 8425

+41 61 324 7188